BARDA

BARDA awarded a new Project BioShield contract to @ShionogiUS to enhance nat'l preparedness for biothreats and multidrug-resistant infections while expanding manufacturing to domestic facilities to build stronger defenses against future health emergencies: ow.ly/Uz1550YRbL1

@LumosDX @US_FDA This program's success demonstrates the value of collaborative #PublicPrivatePartnerships between the U.S. government and product development partners to combat antimicrobial resistance (#AMR). Learn more: medicalcountermeasures.gov/barda/fdaappro…

@LumosDX @US_FDA This rapid diagnostic can help determine if a patient’s acute respiratory infection is caused by a bacterial infection. It can also help inform treatment decisions and reduce unnecessary antibiotic use, which has the potential to improve #AntibioticStewardship. ⬇️

The FebriDx Bacterial/Non-bacterial Assay from @LumosDX is the 110th BARDA-supported product to receive @US_FDA approval, licensure or clearance. The 510(k) clearance & CLIA-waiver expands use of the test in settings like doctor’s offices, pharmacies, etc. ⬇️

BARDA's FASTx solicitation is back! We're funding #PlatformTechnologies that leverage #antiviral conjugates to develop therapeutics against filoviruses and other emerging threats. Learn more here: ow.ly/qv1u50YO4k0

We're advancing an AI-enabled assay from Ad Astra Diagnostics that produces results from a blood sample in less than 3 minutes. QScout CBC is designed to provide meaningful results to frontline providers in ambulances, urgent care centers, clinics & more: ow.ly/ugSS50YFbk1

We’re accepting proposals for a partner to lead the BARDA Accelerator Network Diagnostics and Medical Devices Hub! Submissions are due by 12PM ET on April 20, 2026. Learn more: ow.ly/74H550YEwG1

Today, there are no @US_FDA-approved broad-spectrum therapeutics to treat people with dengue, Zika, West Nile, and Chikungunya and other diseases caused by members of these viral families – but we’re working to change that. BARDA and VITAL, a BARDA Accelerator Network Hub, are partnering to offer prizes to the innovators who can develop novel broad-spectrum antiviral drugs that address this gap in the antiviral pipeline. aspr.hhs.gov/newsroom/Pages…

Together with @CompMedUCLA, we're furthering development of the SwabSeq Metagenomic Diagnostic Platform, designed to detect viral pathogens. It could serve as a rapid response tool to detect a novel respiratory virus in a #HealthSecurity emergency: medicalcountermeasures.gov/barda/dddi

We’re partnering with VITAL, a BARDA Accelerator Network Hub, to administer the SMART Antiviral Prize, a new $100 million prize competition aimed at advancing the development of novel, broad-spectrum, antiviral drugs. Launching in 2026. Get the details: vitalhubhealth.com/antiviral-priz…

Procuring #MedicalCountermeasures that are FDA-approved, licensed, and cleared can help ensure their availability in future health security emergencies. See more in our #CBRN portfolio here: medicalcountermeasures.gov/barda/cbrn

BARDA is bolstering national preparedness through the procurement of multiple #MedicalCountermeasures needed to protect the U.S. population from chemical, biological, radiological, and nuclear (#CBRN) threats.

Treatment courses of the oral suspension of @US_FDA-approved smallpox antiviral TEMBEXA (brincidofovir). This formulation fills a key preparedness gap for patients of all ages who are unable to swallow tablets.

Additional treatment courses of @Amgen’s Nplate, an @US_FDA-approved drug to treat the effects of acute radiation syndrome after a nuclear detonation. Amgen will maintain the product in vendor managed inventory for use in future emergencies.

@FluGenInc @OsivaxVaccines Current flu vaccines, while effective, may not address all variants that could emerge during an influenza pandemic. Therefore, broad-acting vaccines like these could protect against multiple strains and help bolster pandemic preparedness: medicalcountermeasures.gov/barda/influenz…

We’re partnering with @FluGenInc and @OsivaxVaccines to develop innovative #influenza vaccines, which could be used to address both pandemic and seasonal flu. If successful, these vaccines could help bolster national pandemic preparedness efforts.

@FluGenInc @OsivaxVaccines @OsivaxVaccines is developing OVX836, a next-generation, broad-spectrum vaccine. It is designed to provide long-lasting protection against both seasonal and pandemic #influenza A strains, allowing for a universal approach to vaccination during a flu pandemic.

@FluGenInc @OsivaxVaccines @FluGenInc is developing a novel, live-attenuated vaccine candidate that is administered intranasally. This effort could help identify Correlates of Protection biomarkers that may streamline the development pathway for further research and development.

In partnership w/ @CidaraThera, we're developing CD388, a long-acting, antiviral prophylactic for pandemic use. CD388 could protect against seasonal & pandemic #influenza infections when a vaccine is not available or for individuals who can’t receive or don’t respond to vaccines.

Innovators and product developers: Meet with BARDA leaders in San Francisco January 12-15. Act now to request a meeting to discuss your #HealthSecurity technologies and medical countermeasures, and learn about potential funding opportunities: ow.ly/IPZi50XSCTx